Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PD-1-VEGF bispecific antibody (Vicero Bio)
- Development stage
- Preclinical
- Lead developer
- Vicero Bio
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intradermal, Intramuscular, Intraperitoneal, Intravenous, Subcutaneous, Intranasal, Oral, Rectal, Topical, Transdermal, Buccal, Pulmonary, Intracisternal, Intravaginal, Intrasternal, Intraarticular
01
Overview
Vicero Bio's PD-1-VEGF bispecific antibody is an investigational oncology therapeutic developed using the proprietary VINCOBODY platform. This bispecific agent is designed to simultaneously target the Programmed Cell Death Protein 1 (PD-1) immune checkpoint and the Vascular Endothelial Growth Factor (VEGF). By inhibiting PD-1, the antibody aims to restore the anti-tumor activity of exhausted T-cells. Simultaneously, by neutralizing VEGF, it targets tumor angiogenesis and modulates the immunosuppressive tumor microenvironment. This dual-action approach is intended to enhance therapeutic efficacy over single-target agents. The program is currently in the preclinical to early development stage.
- Other names
- PD-1 + VEGF programVINCOBODY PD-1/VEGF bispecific antibody
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)VEGF (VEGF family)
Beyond the preview
Go deeper on PD-1-VEGF bispecific antibody (Vicero Bio).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PD-1-VEGF bispecific antibody (Vicero Bio).